- Home
- LEU vs MNKD Comparison
LEU vs MNKD Comparison
Compare LEU & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- MNKD
- Stock Information
- Founded
- LEU 1998
- MNKD 1991
- Country
- LEU United States
- MNKD United States
- Employees
- LEU N/A
- MNKD N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- MNKD Health Care
- Exchange
- LEU Nasdaq
- MNKD Nasdaq
- Market Cap
- LEU 1.6B
- MNKD 1.4B
- IPO Year
- LEU 1998
- MNKD 2004
- Fundamental
- Price
- LEU $126.92
- MNKD $4.15
- Analyst Decision
- LEU Buy
- MNKD Strong Buy
- Analyst Count
- LEU 6
- MNKD 5
- Target Price
- LEU $143.40
- MNKD $9.40
- AVG Volume (30 Days)
- LEU 1.2M
- MNKD 1.9M
- Earning Date
- LEU 05-07-2025
- MNKD 05-08-2025
- Dividend Yield
- LEU N/A
- MNKD N/A
- EPS Growth
- LEU 40.85
- MNKD 228.27
- EPS
- LEU 6.39
- MNKD 0.10
- Revenue
- LEU $471,400,000.00
- MNKD $297,595,000.00
- Revenue This Year
- LEU $3.22
- MNKD $14.36
- Revenue Next Year
- LEU $9.91
- MNKD $13.36
- P/E Ratio
- LEU $19.85
- MNKD $40.01
- Revenue Growth
- LEU 58.72
- MNKD 32.50
- 52 Week Low
- LEU $33.51
- MNKD $4.05
- 52 Week High
- LEU $136.00
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- LEU 79.42
- MNKD 37.04
- Support Level
- LEU $90.83
- MNKD $4.07
- Resistance Level
- LEU $136.00
- MNKD $4.25
- Average True Range (ATR)
- LEU 7.67
- MNKD 0.16
- MACD
- LEU 3.31
- MNKD -0.03
- Stochastic Oscillator
- LEU 80.15
- MNKD 12.82
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.